Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) traded down 3.4% during trading on Wednesday . The company traded as low as $3.11 and last traded at $3.14, with a volume of 171,016 shares traded. The stock had previously closed at $3.25.

A number of analysts recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a report on Thursday, August 4th. Wedbush reiterated an “outperform” rating and issued a $15.00 target price on shares of Regulus Therapeutics in a report on Wednesday, August 3rd. Wells Fargo & Co. reiterated an “outperform” rating on shares of Regulus Therapeutics in a report on Sunday, July 31st. Chardan Capital dropped their target price on shares of Regulus Therapeutics from $14.50 to $12.00 and set a “buy” rating on the stock in a report on Monday, July 25th. Finally, Zacks Investment Research upgraded shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 6th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $10.17.

The company’s 50-day moving average price is $3.48 and its 200 day moving average price is $5.39. The company’s market cap is $166.91 million.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.02. On average, analysts anticipate that Regulus Therapeutics Inc. will post ($1.59) EPS for the current fiscal year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.